<DOC>
	<DOCNO>NCT01098201</DOCNO>
	<brief_summary>This open-label pilot study select subject inadequate responder methotrexate . These subject receive certolizumab subcutaneously monthly basis six month . The study attempt determine following : 1 . Is lymphatic flow alter extremity RA patient inflame knee ? 2 . Is resolution synovitis associate restoration lymphatic flow lymph node volume follow therapy certolizumab ? 3 . Can Doppler ultrasound use detect follow alteration lymph node size ?</brief_summary>
	<brief_title>Certolizumab Lower Extremity Lymph Flow Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>Ten RA subject unilateral knee synovitis , respond methotrexate , recruit early RA Clinics . Following enrollment , subject technetium sulfur colloid scan perform low extremity follow baseline 3 Tesla contrast-enhanced magnetic resonance imaging ( 3T CE-MRI ) study Doppler US involve knee described . The overall disease activity determine DAS 28 activity involve knee RAOS instrument ; outcome measure quantifies degree tenderness , swell function monoarthritis . The subject receive 18 week certolizumab three ten subject undergo repeat technetium sulfur colloid scan . To test hypothesis , select three responder base RAOS response . We select three 10 repeat nuclear study number subject allow u test hypothesis without need perform scan subject . All ten subject 3T CE-MRI , Doppler US clinical evaluation perform 18 week time point . The subject continue certolizumab total 24 week . Sulfur Colloid Technetium Scan . A nuclear radiology technician inject 0.25cc technetium sulfur colloid first third web space foot low extremity . In healthy control transit time foot aortic bifurcation 30 minute . The transit time tracer measure low extremity knee , inguinal ligament aortic bifurcation . Images obtain nuclear camera accord standard protocol serially first hour delay image acquire 4 6 hour necessary . Three subject respond certolizumab scan repeat 18 week outline . 3T CE-MRI . Two radiologist independently quantify LN volume CE nod popliteal area MRI . These radiologist also quantify extent synovial inflammation , cartilage erosion bone marrow edema via RA MRI score system ( RAMRIS ) . Consensus finding reach volume CE node identify together RAMRIS enter database study . At end study , assess trend anti-TNF therapy : 1 . The number detectable LN popliteal fossa 2 . Mean LN volume detectable LN 3 . Mean LNCE detectable LN 4 . LNcap detectable LN 5 . RAMRIS , plot change 8 week knee independently previously describe anti-TNF effect bone marrow edema PsA subject . The relationship LN clinical response therapy assess derive significance correlation coefficient ( x2 ) LNcap v DAS28 respectively , do bone marrow edema vs. DAS28 PsA subject anti-TNF therapy . Doppler US . Ultrasound examination PLN obtain baseline 18 week anti-TNF therapy follow . All US examination perform rheumatologist ( RT ) certify musculoskeletal ultrasound . All subject examine sonographically presence inflammatory change knee joint . The involved knee examine sonographically presence following : 1 . Effusion . A distension pre-femoral suprapatellar fat pad &gt; 4.8 mm note effusion suprapatellar recess knee joint . 2 . Synovial thickening . Hypoechoic , often nodular villous appear tissue within suprapatellar recess distinct hyperechoic capsular structure prefemoral suprapatellar fat pad note synovitis . 3 . Synovial hyperemia . If proliferative synovial tissue identify , tissue examine Doppler ultrasound presence increase blood flow . This define presence color pixel synovial tissue appear synchronicity subject 's pulse . In subject , affect joint examined gray scale Doppler ultrasound . Affected joint examine sonographically presence following : 1 . Effusion joint define hypoechoic area within hyperechoic joint capsule . Such anechoic intra-articular fluid displaceable pressure US probe . This help distinguish joint fluid intra-articular hyaline cartilage , also anechoic hypoechoic appearance displaceable pressure probe . The distension joint capsule measure use sonographic caliper . This distension compare normal value assess degree effusion . 2 . Synovial thickening . The synovial lining cell one three cell layer strong unaffected joint , intra-articular , hypoechoic proliferative synovial tissue readily distinguish sonographically hyperechoic capsular structure . Thickening , present , measure use sonographic caliper . 3 . Synovial hyperemia . If synovial thickening detect , tissue examine sonographically presence Doppler flow measure hyperemia inflammation . 4 . Bony erosion . Erosions define break cortical bony contour see two perpendicular plane . The dimension PLN image catalog longitudinal analysis . Synovitis erosion also score ultrasound therapy . Outcome Measures : 1 . Technetium sulfur colloid scan 1 . The primary outcome measure study transit time foot umbilicus ( T3 ) injection radioisotope limb inflame knee compare transit time ( T3 ) extremity uninflamed knee . 2 . Secondary outcome measure : - transit time foot knee ( T1 ) inguinal ligament ( T2 ) radioisotope low extremity - Intensity count ( intensity/area interest ) knee , inguinal ligament umbilicus low extremity . - Change transit time tracer intensity three sit 12 week certolizumab treatment involve extremity ( 3 subject ) 2 . MRI ( secondary ) : 1 . The amount contrast enhancement volume drain PLN analyze 18 week treatment certolizumab . 2 . The amount synovitis , joint effusion , erosion bone marrow edema quantify use RAMRIS score system 18 week treatment . 3 . Doppler ultrasound ( secondary ) : 1 . Number detectable LN popliteal fossa . 2 . Mean LN size ( maximum area ) . 3 . Secondary measure : synovitis , joint effusion , erosion , blood flow also assess involve joint . 4 . Clinical Assessments : 1 . Degree tenderness ( 0-3 ) subject visual analogue scale ( VAS ) swell MD VAS ( 0-3 ) inflame treatment . 2 . Rheumatoid Arthritis Outcome Score ( RAOS ) treatment . 3 . Disease Activity Score ( DAS 28 ) score assess overall joint response therapy certolizumab</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Inclusion Inflammatory arthritis . Patients RA accord American College Rheumatology criterion . Inadequate response treatment follow 3 month methotrexate ( 1520 mg per week ) . Inadequate response define presence knee inflammation least 2 active joint . If knee effusion , fluid must obtain exclude infection crystalline disease . Knee inflammation one knee determine physical exam confirm Doppler ultrasound . We include patient bilateral knee inflammation one knee inflame contralateral knee . The comparative level inflammation determine clinical examination Doppler US . Patients must willing undergo sulfur colloid technetium scan , knee ultrasound MRI knee . Exclusion Criteria Contraindication antiTNF agent . History recurrent infection . Prosthetic knee joint Recent surgery trauma knee joint Lymphedema Lymphoproliferative disorder Claustrophobia undergo MRI knee GFR &lt; 60 cc/min Morbid obesity Foot disease : active ankle forefoot synovitis , recent trauma , cellulitis edema . Peripheral vascular disease Diabetes Active skin inflammation low extremity Solid Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Certolizumab</keyword>
	<keyword>TNF</keyword>
	<keyword>RA</keyword>
	<keyword>Cizmia</keyword>
</DOC>